OncoMatch/Clinical Trials/NCT06595186

JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)

Is NCT06595186 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including JK-1201I and Temozolomide (TMZ) for glioblastoma multiforme (gbm).

Phase 2RecruitingJenKem Technology Co., Ltd.NCT06595186Data as of May 2026

Treatment: JK-1201I · Temozolomide (TMZ) — This study was designed to evaluate the safety, tolerability, efficacy and pharmacokinetics of JK-1201I combined with adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme after surgery and concomitant radio-chemotherapy.

Check if I qualify

Extracted eligibility criteria

Cancer type

Glioblastoma

Biomarker criteria

Required: MGMT unmethylation

MGMT unmethylation (only for Dose Expansion Cohort)

Prior therapy

No prior treatment (treatment-naive required)

Must have received: concurrent chemo-radiotherapy

Patients must finish concurrent chemo-radiotherapy (CCRT) no sooner than 4 weeks and no later than 6 weeks

Cannot have received: anti-tumor therapy except for concurrent chemo-radiotherapy (CCRT)

Patients who received anti-tumor therapy except for concurrent chemo-radiotherapy (CCRT)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify